Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse MKT  >  Protalix Biotherapeutics Inc    PLX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
11/29/2016 11/30/2016 12/01/2016 12/02/2016 12/05/2016 Date
0.56(c) 0.56(c) 0.5595(c) 0.31(c) 0.32(c) Last
1 986 358 366 655 114 845 8 951 320 11 272 412 Volume
+14.29% 0.00% -0.09% -44.59% +3.23% Change
More quotes
Financials ($)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
P/E ratio 2013 -
P/E ratio 2014
Capi. / Sales2013 1,97x
Capi. / Sales2014 0,87x
Capitalization 31,0 M
More Financials
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.Its drug... 
More about the company
Surperformance© ratings of Protalix Biotherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
12/02 PROTALIX BIOTHERAPEUTICS : Announces Private Note Exchanges and Private Placemen..
12/02 PROTALIX BIOTHERAPEUTICS, INC. : Regulation FD Disclosure, Other Events, Financi..
12/01 Protalix BioTherapeutics Announces Investor Call
12/01 Protalix BioTherapeutics Announces Private Note Exchanges and Private Placeme..
11/30 PROTALIX BIOTHERAPEUTICS, INC. : Other Events (form 8-K)
11/30 Protalix BioTherapeutics Enrolls First Patient in Phase II Clinical Trial of ..
11/23 PROTALIX BIOTHERAPEUTICS : Alfataliglicerase Approved for Pediatric Indications ..
11/22 PROTALIX BIOTHERAPEUTICS, INC. (NYSE : PLX) Files An 8-K Other Events
11/22 PROTALIX BIOTHERAPEUTICS, INC. : Other Events (form 8-K)
11/22 Alfataliglicerase Approved for Pediatric Indications in Brazil for the Treatm..
More news
Sector news : Biotechnology & Medical Research - NEC
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix Biotherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,50 $
Spread / Average Target 1 036%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Moshe Manor President, Chief Executive Officer & Director
Shlomo Yanai Chairman
Tzvi Palash Chief Operating Officer
Yossi Maimon CFO, Secretary, Treasurer & Vice President
Yoseph Shaaltiel Executive Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PROTALIX BIOTHERAPEUTI..-69.61%31
INCYTE CORPORATION-5.93%19 219
QUINTILES IMS HOLDINGS..7.82%18 225
CELLTRION, INC.--.--%9 953
SEATTLE GENETICS, INC.48.62%9 442
LONZA GROUP AG8.34%9 247
More Results